The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial.

Naser GharebaghiRahim NejadrahimSeyed Jalil MousaviSeyyed-Reza Sadat-EbrahimiReza Hajizadeh

Published in: BMC infectious diseases (2020)

A study protocol was registered at the Iranian Registry of Clinical Trials ( www.IRCT.ir ), number IRCT20200501047259N1 . It was registered retrospectively on May 17th, 2020.

Keyphrases

clinical trial
double blind
placebo controlled
study protocol
phase ii
coronavirus disease
phase iii
open label
randomized controlled trial
phase ii study
high dose
early onset
squamous cell carcinoma
respiratory syndrome coronavirus
low dose